

## Vitiligo: Compendium of clinico-epidemiological features

**Virendra N. Sehgal, Govind Srivastava\***

Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchwati, Azadpur, Delhi and \*Skin institute and School of Dermatology, Greater Kailash, New Delhi, India.

**Address for correspondence:** Dr. Virendra N. Sehgal, A/6, Panchwati, Delhi - 110 033, India, E-mail: drsehgal@ndf.vsnl.net.in

### ABSTRACT

Vitiligo, an autoimmune disorder characterized by localized and / or generalized depigmentation of the skin and / or mucous membranes, is a well-recognized entity. The imperatives of its epidemiology both in rural India and in global reckoning have been highlighted frequently. Its morphology is striking and is characterized by asymptomatic ivory / chalky white macule(s) that may be frequently surrounded by a prominent pigmented border, the 'trichrome vitiligo'. However vitiligo may have morphological variations in the form of: trichrome, quadri-chrome, penta-chrome, blue and inflammatory vitiligo. Its current topographical classification into segmental, zosteriform and nonsegmental, areata, vulgaris, acrofacialis and mucosal represent its well acclaimed presentations. Its adult and childhood onset is well appreciated as also its presentation in males and females. Occasionally, it may be possible to identify triggering factors. Vitiligo may be associated with cutaneous, ocular and systemic disorders, the details of which are discussed in this article.

**Key Words:** Clinical connotation, Definition, Epidemiology, Segmental and Nonsegmental vitiligo, Vitiligo

### REMINISCENCES

Vitiligo is an ancient malady and a historical background will facilitate continuity with current research. The earliest authentic reference of the condition can be traced back to the period of Aushooryan (2200 BC), in the classic Tarikh-e-Tib-e-Iran.<sup>[1]</sup> Pharonic medicine in the Ebers Papyrus (1550 BC) described two types of diseases affecting the color of the skin - (a) with tumors, probably leprosy and (b) with only color change, probably vitiligo. The latter was believed to be treatable.<sup>[2]</sup> Vitiligo occurs worldwide and since time immemorial, world literature is replete with references to the condition and different aspects of its causes and therapy.<sup>[3-10]</sup> Prior to its current nomenclature, it used to be pronounced by several other names, a short resume of which is formed in the following Table 1. 'Vitiligo' appears to have been derived from the Latin word 'vitium', meaning a "defect"<sup>[11,14]</sup> Documentation of the word "vitiligo" is present in the book, De-Medicina, by the Roman physician Celsus.<sup>[15]</sup>

**Table 1: Vitiligo: Historical reminiscence**

Epic (classic) / language	Era (period)	Nomenclature
Buddhist sacred book <sup>[3,11]</sup>	Vinay pitam - 624-544 BC	Kilas (white spotted deer)
Manusmriti <sup>[4]</sup>	200 BC	Suitra
Amarkosha <sup>[3,4]</sup>	600 AD	Suitra - A) Padasphota B) Twakpushpi
Atharva - veda <sup>[5]</sup>	1400 BC	Sweta - Kustha
Arabic medicine <sup>[12]</sup>		Bohak, bahak, baras
Bible <sup>[6]</sup>		Zoraat
Makatomino harai <sup>[1]</sup>	Japanese - 1200 AD	Shirabito

### DEFINITION

Vitiligo is a common, acquired, discoloration of the skin, characterized by well circumscribed, ivory or chalky white macules which are flush to the skin surface. In contrast to this, leukoderma refers to such macules wherein the cause of such a change is known. The hair over the lesion may be either normal or white (poliosis).<sup>[16-23]</sup>

**How to cite this article:** Sehgal VN, Srivastava G. Vitiligo: Compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149-56.

**Received:** December, 2006. **Accepted:** March, 2007. **Source of Support:** Nil. **Conflict of Interest:** Nil.




Figure 1: Vitiligo triggering / precipitating factor(s);<sup>[65-68]</sup> and their possible role in its pathogenesis

**EPIDEMIOLOGY**

Vitiligo occurs worldwide with an overall prevalence of 1%. However, its incidence ranges from 0.1 to > 8.8%<sup>[11,24-29]</sup> across the country and in different countries of the globe. The highest incidence of the condition has been recorded in Indians from the Indian subcontinent, followed by Mexico and Japan [Table 2]. The difference in its incidence may be due to a higher reporting of vitiligo in a population, where an

apparent color contrast and stigma attached to the condition may force them to seek early consultation.<sup>[30-45]</sup> Behl *et al.*<sup>[11,17]</sup> had organized camps in rural areas and industrial pockets in India to evaluate the status of vitiligo. Its incidence was found to be higher in villagers living near dyeing, printing, and carpet industries. A higher incidence of vitiligo in such areas<sup>[17]</sup> may be due to inclusion of cases with chemically induced depigmentation by industrial phenols and quinones, which might have a completely different pathomechanism. Its incidence, however, was relatively low amongst those residing adjoining copper-mines [Table 3].

**Table 2: Vitiligo: Global incidence patterns**

Authors	Year	City / country	Incidence in percentage
El Mofly <sup>[12]</sup>	1968	Egypt / Africa	1
Panja <sup>[30]</sup>	1947	Calcutta / India	6
Levai <sup>[31]</sup>	1958	Vellore / India	4
Punshi and Thakre <sup>[32]</sup>	1969	Amrawati / India	8
Behl and Bhatia <sup>[17]</sup>	1972	Delhi / India	8.8
Sehgal <sup>[33]</sup>	1974	Goa / India	2.9
Koranne and Sachdeva <sup>[34]</sup>	1988	Delhi / India	1.25
Howitz <sup>[35]</sup>	1977	Denmark / Europe	0.38
Grunnet <sup>[36]</sup>	1970	Denmark / Europe	1.44
Dawber <sup>[37]</sup>	1968	England / Europe	0.15
Desmons <sup>[38]</sup>	1974	France/ Europe	
Perrot <sup>[39]</sup>	1973	France / Europe	3.0
Fornara <sup>[40]</sup>	1941	Italy / Europe	0.3
Robert <sup>[8]</sup>	1941	Switzerland / Europe	0.39
Canizares <sup>[41]</sup>	1960	Mexico / United States	4
Ruiz Maldonado <sup>[42]</sup>	1977	Mexico / United States	2.6
Fitzpatrick <sup>[43]</sup>	1974	Massachusetts	8
Arakawa <sup>[44]</sup>	1941	Japan / Other	1.64
Ito <sup>[9]</sup>	1952	Sendai / Other	1.3
Kooh Qoon Teik <sup>[45]</sup>	1962	Malaysia / Other	0.7

Adults and children of both sexes are equally affected although the greater number of reports among females is probably due to the greater social consequences to women and girls affected by this condition.<sup>[11,24,46-53]</sup> However, majority of the vitiligo cases reported begin during the period of active

**Table 3: Vitiligo in rural India: Association with industries<sup>[11,17]</sup>**

City	Number in out-patients	Vitiligo number (%)	Industry
Rajkot	452	136 (30)	Dyeing industries
Dadna	300	20 (7)	Jungle area
Alwar	300	15 (5)	Township
Chandausi	529	146 (28)	Carpet industry
Narnaul	400	1 (0.25)	Bio-farming
Rewari	800	8 (1)	Township
Khetri	320	1 (0.3)	Copper mines
Philakwa	300	30 (10)	Printing industry

Sex and age distribution

growth. Almost half the patients present before the age of 20 years and nearly 70-80% before the age of 30 years.<sup>[53-58]</sup>

### Family history

The proportion of patients with positive family history vary from one part of the world to another. In India, in particular, it ranges from 6.25-18%. In some studies it is as high as 40%. The mode of transmission of vitiligo is quite complex. It is probably polygenic with a variable penetrance.<sup>[53,59-62]</sup>

### Triggering / precipitating factor(s)

It is difficult to precisely define the triggering factors for vitiligo. Nevertheless, it is essential to elicit the details of history of emotional stress, drug intake, infections, trauma / injury (Koebner's phenomenon)<sup>[63]</sup> existent prior to the development of vitiligo lesions<sup>[24,53,64]</sup> Figure 1 attempts to bring into focus the various probable triggering factors in the natural history /development of vitiligo. It is believed that major oxidative stress occurs in vitiligo skin, which is evidenced by low catalase levels and cellular vacuolization in the epidermis<sup>[65,66]</sup> Several factors may contribute to the oxidative stress, thus leading to the accumulation of epidermal hydrogen peroxide. The presence of the hydrogen peroxide can be demonstrated *in vivo* by using noninvasive Fourier transform Raman spectroscopy.<sup>[65-68]</sup> A better understanding of these factors may prove to be helpful in the management of vitiligo.

## CLINICAL FEATURES

Vitiligo is characterized by the appearance of patchy discoloration evident in the form of typical chalky-white or milky macule(s) [Figure 2]. The macules are round and / or oval in shape, often with scalloped margins.<sup>[24,53]</sup> The size of the macules may vary from a few millimeters to several centimeters with the lesions affecting the skin and / or mucous membranes. By and large, the lesions are asymptomatic although itching / burning may precede or accompany the onset of the lesions in a few patients.<sup>[53,69-73]</sup> Vitiligo is a slow and progressive disease and may have remissions and exacerbations correlating with triggering events.<sup>[53,70,74]</sup> Occasionally, the lesions of vitiligo may begin to form around a pigmented nevus<sup>[75]</sup> (Sutton's nevus, leukoderma aquisitum centrifugum) and then go on to affect distant regions.<sup>[52,73]</sup>

Although any part of the skin and / or mucous membranes is amenable to develop vitiligo, the disease has a predilection for normal hyperpigmented regions such as the face, groin, axillae, aerolae and genitalia. Furthermore, lesions may develop in other areas like the ankles, elbows, knees, which

are subjected to repeated trauma / friction, an outcome of Koebner's phenomenon.<sup>[63]</sup> In the event of extensive disease, the lesions are symmetrically distributed<sup>[76-78]</sup> with an exclusive dermatomal distribution or mucous membrane involvement.<sup>[53,79-81]</sup> Lip-tip syndrome, another variant of vitiligo is characterized by depigmentation of the terminal phalanges and the lips.

Vitiligo may show morphological variations in the form of:  
**Trichrome vitiligo:** It is recognized by the presence of a narrow to broad intermediate color zone between a vitiligo macule and normal pigmented surrounding skin [Figure 3]. Hann *et al.*<sup>[82]</sup> had highlighted its clinical and histopathological characteristics and concluded that it is a variant of unstable vitiligo. Cockade-like vitiligo is a variant of trichrome vitiligo.<sup>[83]</sup>

**Quadri-chrome vitiligo:** It is a well-documented fourth color in vitiligo lesions, usually seen in darker skin phenotypes. A macular perifollicular or marginal hyperpigmentation is its salient feature and denotes a repigmenting disease.<sup>[53]</sup>

**Penta-chrome vitiligo:** It is an infrequently encountered variant in which there is a sequential display of white, tan, brown, blue-gray hyperpigmentation and the normal skin. Black-skinned individuals are predisposed to have this disorder.<sup>[84]</sup>

**Blue vitiligo:** It usually corresponds to vitiligo macules occurring at the site of postinflammatory hypermelanosis. Ivkar *et al.*<sup>[85]</sup> reported the development of extensive blue vitiligo following the simultaneous progression of vitiligo and postinflammatory hyperpigmentation in an acquired immunodeficiency syndrome (AIDS) patient.


**Inflammatory vitiligo:** It is an entity which may reveal an erythematous, raised border in a vitiligo macule with frequent itching and / or burning. These changes could be induced by aggressive therapy.<sup>[69,86,87]</sup>

## Classification

Vitiligo is classified into focal, segmental, generalized and universal types, a conventional self-explanatory arrangement.<sup>[24,53,59]</sup> However, Lerner<sup>[59]</sup> classified vitiligo into 3 groups namely: a) segmental [Figure 4], localized, partial or focal vitiligo corresponding to a dermatome / adjacent dermatomes b) vitiligo vulgaris generalized, involving the hands, face, axillae and limbs and c) complete, total or universal vitiligo involving the entire or nearly entire body surface. Behl<sup>[53]</sup> *et al.* had introduced another classification which took cognizance of clinical stage(s) of vitiligo purported to assist or support its management [Table 4].



**Figure 2: Vitiligo vulgaris (generalized): Macules involving extensive body areas on the back**



**Figure 4: (a-b) Segmental vitiligo: Vitiligo zosteriformis before and after PUVA therapy**



**Figure 3: Trichrome vitiligo: Localized chalky white discoloration with pigimentary interface between the normal and depigmented areas**



**Figure 5: Vitiligo areata: Localized chalky white discoloration**

**Table 4: Vitiligo: Prognostic classification<sup>[53]</sup>**

Stage	Clinical features
Progressive vitiligo (V1)	<ul style="list-style-type: none"> <li>Developing new lesions</li> <li>Increasing old lesions</li> <li>Ill-defined borders of the lesion(s)</li> </ul>
Quiescent vitiligo (V2)	<ul style="list-style-type: none"> <li>No appearance of new lesions</li> <li>Stationary old lesions</li> <li>Welldefined, hyper pigmented borders of the lesions</li> </ul>
Improving vitiligo (V3)	<ul style="list-style-type: none"> <li>Decreasing and / or disappearing lesions</li> </ul>

Based on sweat stimulation studies, Koga and Tango divided vitiligo into types A and B.<sup>[88]</sup> Type A was nondermatomal and was considered to be an autoimmune disease that responded to steroids. On the other hand, type B (dermatomal) had shown sympathetic dysfunctions and responded to nialamide. Jerret and Szabo<sup>[89]</sup> had classified vitiligo into absolute and partial (subtypes I and II) depending upon complete or partial absence of melanocytes. After studying the pattern of vitiligo in the Indian context,<sup>[16,32,90]</sup> we suggest a topographical

classification that is helpful in deciding the treatment and prognosis [Table 5].

**ASSOCIATIONS OF VITILIGO**

**Cutaneous associations**

It is important to recapitulate associations of vitiligo as they commonly provide circumstantial evidence to its possible etiopathogenesis. Premature graying of the hair, leukotrichia, halo nevus, lichen planus and alopecia areata are frequently reported associations.<sup>[90-97]</sup> Of these, leukotrichia (poliosis) is found in up to 45%, premature graying of the hair (canities) in 37%, followed by halo nevus in 35% and alopecia areata in up to 10% of cases.<sup>[24,53,55,59]</sup> Occasionally, other skin disorders like dermatitis herpetiformis, giant congenital melanocytic nevus with neurotization, chronic urticaria, nevus depigmentosus, polymorphic light eruption and malignant melanoma have also been recorded in association with vitiligo.<sup>[98-102]</sup> Furthermore, psoriasis vulgaris confined to vitiligo patches and occurring



**Table 5: Vitiligo: Suggested classification**<sup>[16,32,90]</sup>

Segmental	
Vitiligo zosteriformis	Macules distributed along a dermatome or a near dermatome or lines of body cleavage
Non-segmental	
1. Vitiligo areata [Figure 5] (localized, partial or focal) <sup>[59]</sup>	1 or 2 macules
2. Vitiligo acrofacialis	Macules affecting the face and tips of the hands and feet
3. Vitiligo vulgaris (generalized, universal) <sup>[59]</sup>	Generalize macules involving extensive body areas
4. Vitiligo mucosal	An exclusive involvement of mucous membranes

contemporaneously in the same patient has recently been described<sup>[103]</sup> Other interesting autoimmune associations include morphea and Hashimoto's thyroiditis.<sup>[104]</sup> While presenting strong direct and indirect evidence of the autoimmune etiology of alopecia areata, Hordinsky and Ericson,<sup>[105]</sup> stressed its association with vitiligo in many patients.

### Ocular associations

Vogt-Koyanagi-Harada syndrome<sup>[106-111]</sup> refers to the full constellation of vitiligo, poliosis and alopecia with panuveitis and auditory and neurological manifestations. However, iris and retinal pigmentary abnormalities may be present as isolated findings in a few vitiligo patients. Although visual acuity is unaffected in such patients, choroidal abnormalities may be detected in up to 30% and iritis in 5% of vitiligo patients.<sup>[90]</sup> Infrequently, choroidal halo nevus may be associated.<sup>[112-114]</sup>

### Systemic associations

Systemic disorders like hypo / hyperthyroidism, diabetes mellitus, Addisons' disease, pernicious anemia, lymphoma, leukemia and human immunodeficiency virus (HIV) infection, autoimmune polyendocrinopathy candidiasis-ectodermal dystrophy (APECED) are a few of the diseases associated with vitiligo.<sup>[86,90,107-109,115-117]</sup> Egli and Walter<sup>[118]</sup> recently highlighted the association of vitiligo with pernicious anemia while Federman *et al.*<sup>[119]</sup> recorded the occurrence of ulcerative colitis in Vogt Koyanagi-Harada syndrome. Other significant associations include Sjogren syndrome,<sup>[120]</sup> giant cell myocarditis,<sup>[121]</sup> plexopathy<sup>[122]</sup> and amelanotic melanoma.<sup>[123]</sup> Autoimmunity in children and adolescents with vitiligo was studied by Kurtev and Dourmishev to discover its possible role in the etiopathogenesis of vitiligo.<sup>[124]</sup> Autoimmunity and immune responses are of paramount significance in vitiligo, a detailed discussion of which can be found elsewhere.<sup>[125]</sup>

### Childhood (juvenile) vitiligo

Morphological characteristics in childhood (juvenile) vitiligo are more or less identical to those of adult onset vitiligo.

Interestingly, there has been a steady increase in the incidence of childhood vitiligo<sup>[126]</sup> during the past 2 decades.

### DIFFERENTIAL DIAGNOSIS

Numerous dermatoses enter into the differential diagnosis of vitiligo.<sup>[91]</sup> Pityriasis versicolor, nevus depigmentosus, tuberous sclerosis, idiopathic guttate hypomelanosis, Waardenberg's syndrome, systemic sclerosis, pityriasis alba, postinflammatory hypopigmentation, leprosy [tuberculoid tuberculoid (TT)<sup>[126]</sup> borderline tuberculoid (BT), borderline borderline (BB)], melanoma-associated leukoderma, chemical leukoderma, piebaldism and Vogt-Koyanagi-Harada syndrome<sup>[90,127-131]</sup> are some of these dermatoses.

### NATURAL COURSE

The natural course of vitiligo is highly unpredictable. However, after an abrupt onset, the disease may slowly progress for some time followed by a period of stability, which may last for several months to decades. A few of the cases may once again start progressing at a rapid pace after a period of dormancy. Such an occurrence is not uncommon in nonsegmental vitiligo types namely vitiligo vulgaris, acrofacialis and areata. Vitiligo zosteriformis / segmental, however, is the most stable form and may show a better prognosis.<sup>[86-90]</sup> In addition, several other factors may assist in evaluating its prognosis a) the younger the patient, the shorter the duration, the better is the prognosis, b) the lesions located on the fleshy regions of the body may show better chance of recovery in contrast to that on bony / friction points and c) the presence of leukotrichia or lesions on mucous membranes or mucocutaneous junctions may account for a poor prognosis.<sup>[86]</sup>

### REFERENCES

1. Najamabadi M. Tarikh-e-Tib-e-Iran. Vol I. Shamsi: Tehran; 1934.
2. Ebbel B. The Papyrus Ebers Copenhagen. Levin and Munksgaard: 1937. p. 45
3. Charaka S, editor. With translation by the Shree Gulabkunverba Society, Volume 4. Chikitsa Sthana: Jamnagar, India; 1949.
4. Sushrut S, Bhisagratna KK. Vol I, Chaukhamba Sanskrit Sansthan: Varanasi; 1963. p. 354.
5. Whitney WD. Atharva-Veda Samhita. Harvard Oriental series. Vol 7, Harvard University Press: Cambridge; 1905.
6. Goldman L, Moraites RS, Kitzmiller KW. White spots in biblical times. A background for the dermatologist for participation in discussions of current revisions of the bible. Arch Dermatol 1966;93:744-53.
7. Bateman TA. Practical synopsis of cutaneous disease. Johnson J: London; 1813.

8. Robert P. Uber die 'Vitiligo'. *Dermatologica* 1941;4:257-319.
9. Ito M. Vitiligo. *Tohoku J Exp Med* 1952;5:72-6.
10. Banarjee BN, Pal BK. Leukoderma. *Int J Dermatol* 1956;2:1-10.
11. Srivastava G. Vitiligo- Introduction Asian Clinic. *Dermatol* 1994;1:1-5.
12. El Mofty AM. Vitiligo and psoralens. Pergamon Press: Oxford; 1968. p. 1147-95.
13. Carter RL, editor. A Dictionary of Dermatologic Terms. 4<sup>th</sup> ed. Williams and Wilkins: Baltimore, 1992.
14. Fitzpatrick TB. Hypomelanosis. *South Med J* 1964;57:995-1005.
15. Nair BK. Vitiligo-a retrospect. *Int J Dermatol* 1978;17:755-7.
16. Sehgal VN. Vitiligo. Textbook of clinical Dermatology. 4<sup>th</sup> ed. Jaypee: New Delhi; 2004. p. 99-101.
17. Behl PN, Bhatia RK. 400 case of vitiligo - A clinico therapeutic analysis. *Indian J Dermatol* 1971;17:51-4.
18. Punshi SK. Vitiligo. *Q Med Rev* 1979;30:1-46.
19. el Mofty AM, el Mofty M. Vitiligo - a symptom complex. *Int J Dermatol* 1980;19:237-44.
20. Klaus S, Lerner AB. Vitiligo. *J Am Acad Dermatol* 1984;11:997-1000.
21. Scholtz JR. Vitiligo. *Arch Dermatol* 1985;121:21-2.
22. Dunn JF Jr. Vitiligo. *Am Fam Physician* 1986;33:137-43.
23. Sharquie KE. Vitiligo. *Clin Exp Dermatol* 1984;9:117-26.
24. Shwartz RA, Janniger CK. Vitiligo. *Cutis* 1997;60:239-44.
25. Hann SK, Park YK, Chun WH. Clinical feature of vitiligo. *Clin Dermatol* 1997;15:891-7.
26. Kovacs SO. Vitiligo. *J Am Acad Dermatol* 1998;38:647-66.
27. Agarwal G. Vitiligo: An under - estimated problem. *Fam Pract* 1998;15:519-23.
28. Handa S, Kaur I. Vitiligo - Clinical findings in 1436 patients. *J Dermatol Tokyo* 1999;26:653-7.
29. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in caucasian probands and their families. *Pigment Cell Res* 2003;16:208-14.
30. Panja G. Leukoderma. *Indian J Vener Dis* 1947;13:56-63.
31. Levai M. A study of certain contributory factors in the development of vitiligo in South Indian patients. *AMA Arch Derm* 1958;78:364-71.
32. Punshi SK, Thakre RD. Skin survey. *Maharashtra Med J* 1969;16:535-6.
33. Sehgal VN. A clinical evaluation of 202 cases of Vitiligo. *Cutis* 1974;14:439-45.
34. Koranne RK, Sachdeva KG. Vitiligo. *Int J Dermatol* 1988;27:676-81.
35. Howitz J, Brodthagen H, Scheartz M, Thomsen K. Prevalence of Vitiligo. Epidemiological survey on the isle of Bornholm, Denmark. *Arch Dermatol* 1977;113:47-52.
36. Grunnet I, Howitz J, Reymann F, Schwartz M. Vitiligo and pernicious anemia. *Arch Dermatol* 1970;101:82-5.
37. Dawber RP. Vitiligo in Mature onset diabetes mellitus. *Br J Dermatol* 1968;80:275-8.
38. Desmons MF. Le vitiligo de l'enfant. *Bull Soc FR. Dermatol Syphiligr* 1974;81:526-7.
39. Perrot H. Vitiligo, Thyreopallisis et autominunization. *Lyon. Med* 1973;30:325-31.
40. Fornara I. Quoted by Robert P. Uber die vitiligo. *Dermatologica* 1941;4:241-319.
41. Canizares O. Geographic dermatology: Mexico and Central America. *Arch Dermatol* 1960;82:870-93.
42. Ruiz-Maldonado R, Tamayo Sanchez L, Velazquez E. Epidemiology of skin diseases in 10,000 patients of pediatric age. *Bol Med Hosp Infant Max* 1977;34:137-61.
43. Fitzpatrick TB. Phototherapy of vitiligo, in sunlight and man. Normal and abnormal biologic response. */r/ Pathak MA, editor. University of Tokyo Press: Tokyo; 1974. p. 783-91.*
44. Arakawa A. Quoted by Robert P. Uber die Vitiligo, *Dermatologica* 1941;84:257-319.
45. Khoo OT. Vitiligo. A review and report of treatment of 60 cases in the general hospital, Singapore, from 1954 to 1958. *Singapore Med J* 1962;3:157-68.
46. Le Poole C, Boissy RE. Vitiligo. *Semin Cutan Med Surg* 1997;16:3-14.
47. Hann SK, Lee HJ, Segmental vitiligo clinical findings in 208 patients. *J Am Acad Dermatol* 1996;35:671-4.
48. Zaima H, Koga M. Clinical course of 44 cases of localized type vitiligo. *J Dermatol* 2002;29:15-9.
49. Jeninger CK. Childhood vitiligo. *Br J Dermatol* 1993;51:25-8.
50. Halder RM. Childhood Vitiligo. *Clin Dermatol* 1997;15:899-906.
51. Cho S, Kang KC, Hahm JH. Characteristics of vitiligo in Korean children. *Pediatr Dermatol* 2000;17:189-93.
52. Handa S, Dogra S. Epidemiology of childhood vitiligo: A study of 625 patients from North India. *Pediatr Dermatol* 2003;20:207-10.
53. Behl PN, Aggarwal A, Srivastava G. Vitiligo */r/ Behl PN, Srivastava G, editors. Practice of Dermatology. 9<sup>th</sup> ed. CBS Publishers: New Delhi; 2003. p. 238-41.*
54. Herane MI. Vitiligo and leukoderma in children. *Clin Dermatol* 2003;21:283-95.
55. Jaigirdar MQ, Alam SM, Maidul AZ. Clinical presentation of vitiligo. *Mymensingh Med J* 2002;11:79-81.
56. Engel L. What are those white patches in my patient's skin? *Dermatol Nurs* 2001;13:292-7.
57. Lerner MR, Fitzpatrick TB, Halder RM, Hawk JL. Discussion of a case of vitiligo. *Photodermatol Photoimmunol Photomed* 1999;15:41-4.
58. Nordlund JJ, Lerner AB. Vitiligo-it is important. *Arch Dermatol* 1982;118:5-8.
59. Lerner AB. Vitiligo. *J Invest Dermatol* 1959;32:285-310.
60. Westerhof W. Vitiligo-a window in the darkness. *Dermatology* 1995;190:181-2.
61. Goudie BM, Wilkieson C, Goudie RB. Skin maps in vitiligo. *Scott Med J* 1983;28:343-6.
62. Gauthier Y, Cario-Andre M, Lepreux S, Pain C, Taieb A. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. *Br J Dermatol* 2003;148:95-101.
63. Pegum JS. Vitiligo. *Br J Dermatol* 1996;134:373.
64. Behl PN. Review of therapeutic measures in the treatment of vitiligo. *Indian J Dermatol Venereol* 1957;23:17-24.
65. Schallreuter KU, Moore J, Behrens-Williams S, Panske A, Harari M. Rapid initiation of re-pigmentation in vitiligo with dead sea climatotherapy in combination with pseudo catalase. *Int J Dermatol* 2002;41:482-7.

66. Schallreuter KU. Successful treatment of oxidative stress in vitiligo. *Skin Pharmacol Appl Skin Physiol* 1999;12:132-8.
67. Ortonne JP. Psoralen therapy in vitiligo. *Clin Dermatol* 1989;7:120-35.
68. Orecchia G, Perfett L. Phototherapy with topical khellin and sunlight in vitiligo. *Dermatology* 1992;184:120-3.
69. Arata J, Abe-Matsuura Y. Generalized vitiligo preceded by a generalized figurate erythematous eruption. *J Dermatol* 1994;21:438-41.
70. Abdel-Naser MB, Ludwig WD, Gollnick H, Orfanos CE. Non segmental vitiligo decrease of the CD45RA+ T-cell subset and evidence for peripheral T-cell activation. *Int J Dermatol* 1992;31:321-6.
71. Nordlund JJ. The signification of depigmentation. *Pigment Cell Res* 1992;2:237-41.
72. Al'Abadie MS, Warren MA, Bleehen SS, Gawkrödger DJ. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. *Int J Dermatol* 1995;34:837-40.
73. Fisher AA. Differential diagnosis of idiopathic vitiligo from contact leukoderma. Part II: Leukoderma due to cosmetics and bleaching creams. *Cutis* 1994;53:232-4.
74. Goudie RB, Spence JC, Mackie R. Vitiligo patterns stimulating autoimmune and rheumatic diseases. *Lancet* 1979;2:393-5.
75. Wayne DM, Helwig EB. Halo nevi. *Cancer* 1968;22:69-90.
76. Wee TA. A case report of extensive vitiligo. *Hawaii Med J* 1997;56:37-40.
77. Drake L, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, *et al.* Guidelines of care for vitiligo patients. *J Am Acad Dermatol* 1996;35:620-6.
78. Hann SK, Chun WH, Park YK. Clinical characteristics of progressive vitiligo. *Int J Dermatol* 1997;36:353-5.
79. Hautmann G, Panconesi E. Vitiligo: A psychologically influencing disease. *Clin Dermatol* 1997;15:879-90.
80. Mathias CG, Maibach HI, Conant MA. Perioral leukoderma stimulating vitiligo from use of toothpaste containing cinnamic aldehyde. *Arch Dermatol* 1980;116:1172-3.
81. O'Sullivan JJ, Stevenson CJ. Screening for occupational vitiligo in workers exposed to hydroquinone monomethyl ether and to para tertiary-amyl-phenol. *Br J Ind Med* 1981;38:381-3.
82. Hann SK, Kim YS, Yoo JH, Chun YS. Clinical and histological characteristic of trichrome vitiligo. *J Am Acad Dermatol* 2000;42:589-96.
83. Dupre A, Christol B. Cockade - like vitiligo and linear vitiligo a variant of Fitzpatrick's trichrome vitiligo. *Arch Dermatol Res* 1978;262:197-203.
84. Fargnoli MC, Bolognia JL. Pentachrome vitiligo. *J Am Acad Dermatol* 1995;33:853-6.
85. Ivker R, Goldaber M, Buchness MR. Blue vitiligo. *J Am Acad Dermatol* 1994;30:829-31.
86. Michaelsson G. Vitiligo with raised borders- report of two cases. *Acta Derm Venereol* 1968;48:158-61.
87. Fisher AA. Differential diagnosis of idiopathic vitiligo: Part III: Occupational leukoderma. *Cutis* 1994;53:278-80.
88. Koga M, Tango T. Clinical features and course of type A and type B vitiligo. *Br J Dermatol* 1988;118:223-8.
89. Jarrett A, Szabo G. The pathological varieties of vitiligo and their response to treatment with meladinine. *J Dermatol* 1956;68:313-26.
90. Sehgal VN, Rege VL, Mascarenhas F, Kharangate VN. Clinical pattern of vitiligo amongst Indians. *J Dermatol Tokyo* 1976;3:49-53.
91. Ortonne JP, Bahadoran P, Fitzpatrick TB. Hypomelanoses and hypermelanosis. *In: Freeberg IM, Eisen AZ, Wolff K, Austen K F, Gold Smith LA, Katz SI, Fitzpatrick TB, editors. Dermatology in general medicine.* Mc Graw-Hill: New York; 1999. p. 836-47.
92. Adams BB, Lucky AW. Colocalization of alopecia areata and vitiligo. *Pediatr Dermatol* 1999;16:364-6.
93. Smyth JR Jr, McNeil M. Alopecia areata and universalis in the Smyth-chicken model for spontaneous autoimmune vitiligo. *J Investig Dermatol Symp Proc* 1999;4:211-5.
94. Khandpur S, Reddy BS. An association of 20 nails dystrophy with vitiligo. *J Dermatol* 2001;28:38-42.
95. Lee D, Lazova R, Bolognia JL. A figurate papulosquamous variant of inflammatory vitiligo. *Dermatology* 2000;200:270-4.
96. Wayte J, Wilkinson JD. Unilateral lichen planus sparing the vitiliginous skin. *Br J Dermatol* 1995;133:817-8.
97. Anstey A, Marks R. Co-localization of lichen planus and vitiligo. *Br J Dermatol* 1993;128:103-4.
98. Amato L, Gallerani I, Fuligni A, Mei S, Fabbri P. Dermatitis herpetiformis and vitiligo: Report of a case and review of the literature. *J Dermatol* 2000;27:462-6.
99. De Sica AB, Wakelin S. Psoriasis vulgaris confined to vitiligo patches and occurring contemporaneously in the same patients. *Clin Exp Dermatol* 2004;29:434-5.
100. Dervis E, Acbay O, Barut G, Karaoglu A, Ersoy L. Association of vitiligo, morphea and Hashimoto's thyroiditis. *Int J Dermatol* 2004;43:236-7.
101. Hordinsky M, Ericson M. Autoimmunity: Alopecia areata. *J Investig Dermatol Symp Proc* 2004;9:73-8.
102. Shin JH, Kim MJ, Cho S, Whang KK, Hahn JH. A case of giant congenital nevocytic nevus with necrotization and on set of vitiligo. *J Eur Acad Dermatol Venereol* 2002;16:384-6.
103. Midelfart K, Moseng D, Kavli G, Stenvold SE, Volden G. A case of chronic urticaria and vitiligo, associated with thyroiditis, treated with PUVA. *Dermatologica* 1983;167:39-41.
104. Kang IK, Hann SK. Vitiligo coexistent with nevus dedepigmentosus. *J Dermatol Tokyo* 1996;23:187-90.
105. Downs AM, Lear JT, Dunnill MG. Polymorphic light eruption limited to areas of vitiligo. *Clin Exp Dermatol* 1999;24:379-81.
106. IX. Malignant melanoma and vitiligo. *J Invest Dermatol* 1979;73:491-4.
107. Nordlund JJ, Albert D, Forget B, Lerner AB. Halo nevi and Vogt Koyanagi- Harada syndrome - manifestation of vitiligo. *Arch Dermatol* 1980;116:690-2.
108. Kumakiri M, Kimura T, Miura Y, Tagawa Y. Vitiligo with an inflammatory erythema in Vogt - Koyanagi- Harada disease: Demonstration of filamentous masses and amyloid deposits. *J Cutan Pathol* 1982;9:258-66.
109. Barnes L. Vitiligo and Vogt Koyanagi- Harada syndrome. *Dermatol Clin* 1988;6:229-39.
110. Egli F, Walter R. Images in clinical medicine. Vitiligo and pernicious anemia. *N Engl J Med* 2004;350:2698.
111. Federman DG, Kravetz JD, Ruser CB, Judson PH, Kirsner RS. Vogt-Koyanagi-Harada syndrome and ulcerative colitis. *South Med J* 2004;97:169-71.

112. Okada T, Sakamoto T, Ishibashi T, Inomata H. Vitiligo in Vogt-Koyanagi-Harada disease: Immunohistological analysis of inflammatory site. *Graefes Arch Clin Exp Ophthalmol* 1996;234:359-63.
113. Tsuruta D, Hamada T, Teramae H, Mito H, Ishii M. Inflammatory vitiligo in Vogt-Koyanagi-Harada disease. *J Am Acad Dermatol* 2001;44:129-31.
114. Fournier GA, Albert DM, Wagoner MD. Choroidal halo nevus occurring in a patient with vitiligo. *Surv Ophthalmol* 1984;28:671-2.
115. Kim YC, Park HJ, Cinn YW. Phakomatosis pigmentovascularis type IIa with generalized vitiligo. *Br J Dermatol* 2002;147:1028-9.
116. Fisher AA. The role of ocular disturbance in the differentiation of idiopathic vitiligo from contact leukoderma. *Cutis* 1995;55:61.
117. Feinstein A, Kahana M, Schewach-Millet M, Levy A. Idiopathic calcinosis and vitiligo of the scrotum. *J Am Acad Dermatol* 1984;11:519-20.
118. Stork J, Nemcova D, Hoza J, Kodetova D. Eosinophilic fasciitis in an adolescent girl with lymphadenopathy and vitiligo-like and linear scleroderma-like changes. A case report. *Clin Exp Rheumatol* 1996;14:337-41.
119. Montes LF, Pfister R, Elizalde F, Wilborn W. Association of vitiligo with Sjogren's syndrome. *Acta Derm Venereol* 2003;83:293.
120. Stevens AW, Grossman ME, Barr ML. Orbital myositis, vitiligo and giant cell myocarditis. *J Am Acad Dermatol* 1996;35:310-2.
121. Stollberger C, Finsterer J, Angel K, Eggl-Tyl E. Unusual cause of leg oedema and plexopathy in a patient with vitiligo. *Acta Med Austriaca* 2000;27:160-2.
122. Takematsu H, Tomita Y, Sato A, Seiji M. An amelanotic melanoma transformed into melanotic melanoma with development of vitiligo. *J Dermatol Tokyo* 1981;8:431-8.
123. Sehgal VN. *Clinical leprosy*. 4<sup>th</sup> ed. Jaypee Brothers: New Delhi; 2004.
124. Kurtev A, Dourmishev AL. Thyroid function and auto-immunity in children and adolescents with vitiligo. *J Eur Acad Dermatol Venereol* 2004;18:109-11.
125. Sehgal VN, Srivastava G. Vitiligo: Auto-immunity and immune responses. *Int J Dermatol* 2006;45:583-90.
126. Halder RM, Grimes PE, Cowan CA, Enterline JA, Chakrabarti SG, Kenney JA Jr. Childhood vitiligo. *J Am Acad Dermatol* 1987;16:948-54.
127. Verma S, Kumar B. Contact leukoderma of the scalp or an unusual variant of vitiligo. *J Dermatol* 2001;28:554-6.
128. Silvestre JF, Botella R, Ramon R, Guijarro J, Betlloch I, Morell AM. Periumbilical contact vitiligo appearing after allergic contact dermatitis to nickel. *Am J Contact Dermatitis* 2001;12:43-4.
129. Kossard S, Commens C. Hypopigmented malignant melanoma simulating vitiligo. *J Am Acad Dermatol* 1990;22:840-2.
130. Sanchez JL, Vazquez M, Sanchez NP. Vitiligo-like macules in systemic scleroderma. *Arch Dermatol* 1983;119:129-33.
131. Saha KC, Arya M, Saha AK. Neurohistological studies in lichen planus and vitiligo. *Indian J Dermatol* 1979;24:51-5.